FRA
WST icon

Front Row Advisors’s West Pharmaceutical WST Stock Holding History

Front Row Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-43
Closed -$10K – 1027
2020
Q2 		$10K Sell
43
-315
-88% -$61.9K 0.01% 481
2020
Q1 		$68K Buy
358
+298
+497% +$45.9K 0.05% 179
2019
Q4 		$9K Sell
60
-3
-5% -$437 0.01% 487
2019
Q3 		$9K Buy
63
+13
+26% +$1.79K 0.01% 471
2019
Q2 		$6K Hold
50
– – ﹤0.01% 561
2019
Q1 		$6K Buy
50
+1
+2% +$104 ﹤0.01% 555
2018
Q4 		$5K Sell
49
-26
-35% -$2.82K ﹤0.01% 561
2018
Q3 		$8K Hold
75
– – 0.01% 473
2018
Q2 		$7K Hold
75
– – ﹤0.01% 530
2018
Q1 		$7K Buy
+75
New +$7.02K ﹤0.01% 509

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Front Row Advisors's WST Position: Q3 2020 in Review

Front Row Advisors sold out of West Pharmaceutical (WST) in Q3 2020, closing a stake of 43 shares — an estimated $10K sold.

Front Row Advisors first reported a position in WST in Q1 2018 and held it in 10 quarters. The position peaked at $68K in Q1 2020. 574 funds tracked by Wall St. Rank hold WST as of Q3 2020.

  • Front Row Advisors reported no remaining West Pharmaceutical position as of Q3 2020 after selling out during the quarter.
  • Front Row Advisors sold 43 West Pharmaceutical shares in Q3 2020, an estimated $10K.
  • Front Row Advisors first reported a position in West Pharmaceutical in Q1 2018 and held it in 10 quarters.
  • Front Row Advisors's West Pharmaceutical position peaked at $68K in Q1 2020.
  • 574 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2020.

Based on Front Row Advisors's 13F filing for Q3 2020, filed 30 Nov 2020.